Results 271 to 280 of about 911,530 (311)

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

Lancet, The, 2023
Arvind Dasari, Sara Lonardi, Elena Elez
exaly  

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

Lancet, The, 2021
Saad Z Usmani, Alfred Garfall, Hareth Nahi   +2 more
exaly  

KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study

Lancet, The, 2021
Bijal Shah, Armin Ghobadi, Aaron C Logan
exaly  

Advanced reperfusion strategies for patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation (ARREST): a phase 2, single centre, open-label, randomised controlled trial

Lancet, The, 2020
Demetris Yannopoulos, Ganesh Raveendran, Thomas A Murray   +2 more
exaly  

REFRACTORY ANÆMIA

Medical Journal of Australia, 1942
openaire   +2 more sources

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

Lancet, The, 2022
Jon Arnason, Stephan Mielke, Koji Izutsu
exaly  

The Refractory Endometrium is Still Refractory

Journal of Obstetrics and Gynaecology Canada, 2017
Michael John, Coles, Nicole, Palmer, Robert, Casper   +2 more
openaire   +2 more sources

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Lancet, The, 2021
Jesus G Berdeja, Deepu Madduri, Saad Z Usmani   +2 more
exaly  

Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial

Lancet, The, 2012
Nicole M Ryan, Surinder S Birring, Peter G Gibson   +2 more
exaly  

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

Lancet, The, 2020
Athanasios Dimopoulos, Hang Quach, María-Victoria Mateos   +2 more
exaly